68
Participants
Start Date
September 29, 2021
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Avelumab
oral
Lorlatanib
oral
Talazoparib
oral
Pemetrexed
IV (intravenous) infusion
Axitinib
oral
CMP 001
IT (intratumoral) or SC (subcutaneous)
Utomilumab
IV infusion
PF04518600
IV infusion
Chang Gung Medical Foundation-Linkou Branch, Taoyuan District
National Cheng Kung University Hospital, Tainan City
Auckland City Hospital, Auckland
Országos Onkológiai Intézet, Budapest
Mater Hospital Sydney, Wollstonecraft
Melanoma Institute Australia, Wollstonecraft
Macquarie University, North Ryde
The Prince Charles Hospital, Chermside
Grand Hôpital de Charleroi, Gilly
UZ Gent, Ghent
Aalborg Universitetshospital, Syd, Aalborg
National Taiwan University Hospital, Taipei
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
Memorial Sloan Kettering Cancer Center 53rd street., New York
Memorial Sloan Kettering Cancer Center, New York
National Cancer Center, Goyang-si
MSK Westchester, Harrison
Institute for Oncology and Radiology of Serbia, Belgrade
MSK Nassau, Uniondale
MSK Commack, Commack
Seoul National University Bundang Hospital, Seongnam
Hospital of the University of Pennsylvania, Philadelphia
IRCCS Istituto Clinico Humanitas, Rozzano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Gachon University Gil Medical Center, Namdong-gu
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Moffitt Cancer Center, Tampa
Hospital Universitario Virgen de Valme, Seville
Institut de Cancérologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona
"Hospital Universitario Dr. Jose Eleuterio Gonzalez", Monterrey
Oaxaca Site Management Organization S.C., Oaxaca City
Highlands Oncology Group, PA, Fayetteville
Highlands Oncology Group, PA, Rogers
Highlands Oncology Group, PA, Springdale
The University of Texas MD Anderson Cancer Center, Houston
UCLA Hematology/Oncology, Los Angeles
Fred Hutchinson Cancer Center, Seattle
Moscow Scientific Research Oncology Institute n.a. P.A. Hertzen, Moscow
"Private Medical Institution Euromedservice", Pushkin
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary, Pyatigorsk
SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan, Ufa
"FBIH Privolzhskiy Regional Medical Center of FMBA", Nizhny Novgorod
"Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary", Omsk
Rabin Medical Center, Petah Tikva
MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale
Cross Cancer Institute, Edmonton
Kingston Health Sciences Centre-Kingston General Hospital Site, Kingston
Oita University Hospital, Yufu
National Cancer Center Hospital, Chuo-ku
Japanese Foundation for Cancer Research, Koto
National Hospital Organization Kyushu Cancer Center, Fukuoka
Centralny Szpital Kliniczny MSWiA w Warszawie, Warsaw
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warsaw
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clínic de Barcelona, Barcelona
Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat
Royal Marsden Hospital (Chelsea), London
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Royal Cornwall Hospitals NHS Trust, Truro
Lead Sponsor
Pfizer
INDUSTRY